Big Pharma Accused of Free-Riding on Nature as Biodiversity Fund Stalls at $7,000
Big pharma is accused of exploiting nature's genetic resources for profit while failing to contribute meaningfully to a global biodiversity fund, which has attracted a negligible sum despite its massive potential. This story explores the ethical gap between scientific advancement and ecological responsibility.